|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Nantes University Hospital |
|---|---|
| Information provided by: | Nantes University Hospital |
| ClinicalTrials.gov Identifier: | NCT00467506 |
Purpose
Phase II clinical trial assessing efficacy and toxicity of pretargeted radioimmunotherapy using anti-CEAxanti-DTPA bispecific antibody and di-DTPA-131I peptide in patients with reccurrence of medullary thyroid carcinoma (abnormal calcitonin level and biomarkers doubling time lower than 5 years)
| Condition | Intervention | Phase |
|---|---|---|
|
Thyroid Neoplasms |
Drug: bispecific antibody and di-DTPA-131I |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Factorial Assignment, Safety/Efficacy Study |
| Official Title: | Phase II Two-Step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Contacts and Locations| Contact: Françoise Pr F. Kraeber-Bodéré, MD | 0033 2 40 08 47 47 | Francoise.bodere@chu-nantes.fr |
| France | |
| Centre René Gauducheau | Recruiting |
| Saint Herblain, France, 440805 | |
| Sub-Investigator: boumédienne Bridgi, MD | |
| Sub-Investigator: Isabelle Resche, MD | |
| Principal Investigator: Caroline Rousseau, MD | |
| CHU | Recruiting |
| Nantes, France, 44093 | |
| Principal Investigator: Francoise Bodere, MD | |
| CHU | Recruiting |
| Lyon, France, 69394 | |
| Principal Investigator: Françoise borson-Chazot, MD | |
| Sub-Investigator: Claire Houzard, MD | |
| Sub-Investigator: Agnes Perrin, MD | |
| CHU de Grenoble | Recruiting |
| Grenoble, France, 38043 | |
| Principal Investigator: Jean Philippe Vuillez, MD | |
| Sub-Investigator: Olivier Chavre, MD | |
| Hôpital de la Piitié Salpétrière | Recruiting |
| Paris, France, 75 651 | |
| Principal Investigator: C Guillausseau, MD | |
| Hôpital Cochin | Recruiting |
| Paris, France, 75679 | |
| Principal Investigator: florence Tenembaum, MD | |
| CHU | Recruiting |
| Rouen, France, 76230 | |
| Principal Investigator: Jean Marc Khun, MD | |
| hôpital du Cluzeau | Recruiting |
| Limoges, France, 87042 | |
| Principal Investigator: F Archanbeau, MD | |
| Centre François Baclesse | Recruiting |
| Caen, France, 14076 | |
| Principal Investigator: Stéphane Bardet, MD | |
| Centre René Huguenin | Recruiting |
| Saint Cloud, France, 92210 | |
| Principal Investigator: Carine Corone, MD | |
| Centre Claudius Régaud | Recruiting |
| Toulouse, France, 31052 | |
| Principal Investigator: frederic Courbon, MD | |
| Centre Paul Strauss | Recruiting |
| Strasbourg, France, 67065 | |
| Hôpital de la timone | Recruiting |
| Marseille, France, 13385 | |
| Sub-Investigator: Bernard Conte devolx, MD | |
| Principal Investigator: Mundler, MD | |
| Principal Investigator: | Francoise Bodere, MD | CHU de Nantes |
More Information
| Study ID Numbers: | BRD 03/2-U |
| Study First Received: | April 27, 2007 |
| Last Updated: | April 27, 2007 |
| ClinicalTrials.gov Identifier: | NCT00467506 |
| Health Authority: | France: Afssaps - French Health Products Safety Agency |
|
Recurrence of medullary thyroid carcinoma: abnormal calcitonin level and biomarkers doubling time lower than 5 years after initial surgery |
|
Calcitonin Thyroid Neoplasms Endocrine System Diseases Salmon calcitonin Recurrence Antibodies, Bispecific Carcinoma Calcitonin Gene-Related Peptide |
Antibodies Head and Neck Neoplasms Thyroid cancer, medullary Endocrinopathy Thyroid Diseases Neoplasms, Glandular and Epithelial Endocrine Gland Neoplasms Immunoglobulins |
|
Neoplasms Neoplasms by Site Neoplasms by Histologic Type |
Immunologic Factors Physiological Effects of Drugs Pharmacologic Actions |
